Lexicon Pharmaceuticals, Inc. (LXRX)
2.24
-0.02
(-0.88%)
USD |
NASDAQ |
Sep 04, 16:00
2.235
0.00 (0.00%)
After-Hours: 20:00
Lexicon Pharmaceuticals Research and Development Expense (Quarterly) : 17.34M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 17.34M |
| March 31, 2026 | 12.65M |
| December 31, 2025 | 11.20M |
| September 30, 2025 | 18.61M |
| June 30, 2025 | 15.57M |
| March 31, 2025 | 15.13M |
| December 31, 2024 | 25.46M |
| September 30, 2024 | 25.65M |
| June 30, 2024 | 17.50M |
| March 31, 2024 | 14.23M |
| December 31, 2023 | 14.62M |
| September 30, 2023 | 17.41M |
| June 30, 2023 | 14.40M |
| March 31, 2023 | 11.91M |
| December 31, 2022 | 13.87M |
| September 30, 2022 | 10.45M |
| June 30, 2022 | 13.25M |
| March 31, 2022 | 14.82M |
| December 31, 2021 | 16.39M |
| September 30, 2021 | 15.58M |
| June 30, 2021 | 10.22M |
| March 31, 2021 | 12.57M |
| December 31, 2020 | 0.648M |
| September 30, 2020 | 37.16M |
| June 30, 2020 | 56.90M |
| Date | Value |
|---|---|
| March 31, 2020 | 54.68M |
| December 31, 2019 | 40.17M |
| September 30, 2019 | 26.15M |
| June 30, 2019 | 12.64M |
| March 31, 2019 | 12.02M |
| December 31, 2018 | 12.31M |
| September 30, 2018 | 13.24M |
| June 30, 2018 | 26.48M |
| March 31, 2018 | 47.70M |
| December 31, 2017 | 47.16M |
| September 30, 2017 | 39.14M |
| June 30, 2017 | 26.93M |
| March 31, 2017 | 43.58M |
| December 31, 2016 | 40.40M |
| September 30, 2016 | 52.53M |
| June 30, 2016 | 48.22M |
| March 31, 2016 | 37.00M |
| December 31, 2015 | 30.44M |
| September 30, 2015 | 23.11M |
| June 30, 2015 | 20.77M |
| March 31, 2015 | 20.86M |
| December 31, 2014 | 20.03M |
| September 30, 2014 | 24.01M |
| June 30, 2014 | 19.99M |
| March 31, 2014 | 20.35M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Viatris, Inc. | 245.20M |
| Pfizer Inc. | 2.746B |
| ANI Pharmaceuticals, Inc. | 14.75M |
| Corcept Therapeutics, Inc. | 53.89M |
| Veru, Inc. | 4.353M |